Sotera Health (NASDAQ:SHC) Stock Gets Price Target Trim from JPMorgan Chase & Co.

Sotera Health (NASDAQ:SHC) had its price target lowered by investment analysts at JPMorgan Chase & Co. from $17.00 to $15.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 8.56% from the company’s previous close.

A number of other analysts have also recently weighed in on SHC. Citigroup increased their price target on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Weiss Ratings lowered Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Piper Sandler restated an “overweight” rating and set a $25.00 price objective on shares of Sotera Health in a research note on Tuesday, September 8th. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday, October 25th. Finally, Barclays cut their target price on Sotera Health from $22.00 to $20.00 and set an “overweight” rating on the stock in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.88.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded up $0.38 during trading on Wednesday, reaching $16.41. The stock had a trading volume of 3,015,531 shares, compared to its average volume of 2,704,585. Sotera Health has a one year low of $13.09 and a one year high of $19.85. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. The stock has a market cap of $4.68 billion, a PE ratio of 28.81 and a beta of 1.94. The firm’s 50 day moving average price is $18.42 and its two-hundred day moving average price is $17.02.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.02. The firm had revenue of $324.89 million for the quarter, compared to analysts’ expectations of $319.86 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business posted $0.26 earnings per share. On average, research analysts forecast that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Insider Activity at Sotera Health

In other news, insider Michael P. Rutz sold 150,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the completion of the transaction, the insider directly owned 334,279 shares in the company, valued at approximately $6,297,816.36. The trade was a 30.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman directly owned 3,969,393 shares of the company’s stock, valued at $73,433,770.50. This trade represents a 17.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 1,294,515 shares of company stock valued at $23,999,528. Insiders own 15.36% of the company’s stock.

Institutional Investors Weigh In On Sotera Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Sotera Health in the 2nd quarter valued at about $428,635,000. Sculptor Capital LP bought a new stake in shares of Sotera Health during the 2nd quarter worth about $426,000,000. Jupiter Topco LLC bought a new stake in shares of Sotera Health during the 2nd quarter worth about $149,137,000. Two Seas Capital LP bought a new stake in shares of Sotera Health during the 2nd quarter worth about $103,590,000. Finally, Lakewood Capital Management LP acquired a new stake in shares of Sotera Health in the 2nd quarter worth approximately $70,638,000. 91.03% of the stock is currently owned by institutional investors.

Trending Headlines about Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q3 revenue rose 4.4% year over year to $324.9 million, topping analyst expectations of about $319.9 million. Adjusted EPS was $0.29 versus the $0.27 consensus and increased 12% year over year; adjusted EBITDA rose 3.9%. Sotera Health Q3 results
• Neutral Sentiment: Management reaffirmed its 2026 outlook: constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. It also provided fourth-quarter revenue guidance, though the supplied report did not include the forecast figure. Fourth-quarter revenue guidance
• Negative Sentiment: The company cited softness in the European medical-device market, a demand headwind investors will monitor despite the reaffirmed full-year targets. 2026 outlook and European market conditions

About Sotera Health

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.